Literature DB >> 20460907

Environmental and genetic determinants of fatty liver in humans.

Konstantinos Kantartzis1, Fritz Schick, Hans-Ulrich Häring, Norbert Stefan.   

Abstract

Non-alcoholic fatty liver represents one of the most prevalent conditions affecting about one third of the general population in the Western world, and its prevalence is continuously increasing parallel to the epidemics of obesity. Non-alcoholic fatty liver is a strong predictor of non-alcoholic steatohepatitis, but also of cirrhosis, end-stage liver disease and hepatocellular carcinoma. In recent years, non-alcoholic fatty liver (in addition to overall and visceral obesity) has emerged as a risk factor for insulin resistance, hypertension, dyslipidemia, cardiovascular events and type 2 diabetes. This review summarizes the information currently available about the mechanisms involved in liver fat accumulation (e.g. hepatic lipid supply, de novo lipogenesis, lipid oxidation and the packaging and secretion of triglycerides in the form of very-low-density lipoproteins). New aspects concerning mechanisms potentially leading to a 'dissociation' of fatty liver and insulin resistance are also discussed. Understanding the pathogenesis of fatty liver and its complications, including the identification of new factors secreted from the liver under excess fat accumulation that are involved in the regulation of metabolism ('hepatokines'), is crucial in order to develop and implement efficient prevention and treatment strategies. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460907     DOI: 10.1159/000282082

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  9 in total

1.  Template to improve glycemic control without reducing adiposity or dietary fat.

Authors:  R Krishnapuram; E J Dhurandhar; O Dubuisson; H Kirk-Ballard; S Bajpeyi; N Butte; M S Sothern; E Larsen-Meyer; S Chalew; B Bennett; A K Gupta; F L Greenway; W Johnson; M Brashear; G Reinhart; T Rankinen; C Bouchard; W T Cefalu; J Ye; R Javier; A Zuberi; N V Dhurandhar
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-01-25       Impact factor: 4.310

2.  Increased selenoprotein p levels in subjects with visceral obesity and nonalcoholic Fatty liver disease.

Authors:  Hae Yoon Choi; Soon Young Hwang; Chang Hee Lee; Ho Cheol Hong; Sae Jeong Yang; Hye Jin Yoo; Ji A Seo; Sin Gon Kim; Nan Hee Kim; Sei Hyun Baik; Dong Seop Choi; Kyung Mook Choi
Journal:  Diabetes Metab J       Date:  2013-02-15       Impact factor: 5.376

3.  Predictors of impaired glucose regulation in patients with non-alcoholic fatty liver disease.

Authors:  Erifili Hatziagelaki; Drosos E Karageorgopoulos; Athina Chounta; Anastasia Tsiavou; Matthew E Falagas; George Dimitriadis
Journal:  Exp Diabetes Res       Date:  2011-09-21

4.  Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass.

Authors:  Birgit Knebel; Jutta Haas; Sonja Hartwig; Sylvia Jacob; Cornelia Köllmer; Ulrike Nitzgen; Dirk Muller-Wieland; Jorg Kotzka
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

5.  Hog millet (Panicum miliaceum L.)-supplemented diet ameliorates hyperlipidemia and hepatic lipid accumulation in C57BL/6J-ob/ob mice.

Authors:  Mi-Young Park; Hwan-Hee Jang; Jung Bong Kim; Hyun Nye Yoon; Jin-Young Lee; Young-Min Lee; Jae-Hyun Kim; Dong-Sik Park
Journal:  Nutr Res Pract       Date:  2011-12-31       Impact factor: 1.926

6.  Integrated Haematological Profiles of Redox Status, Lipid, and Inflammatory Protein Biomarkers in Benign Obesity and Unhealthy Obesity with Metabolic Syndrome.

Authors:  Carla Lubrano; Giuseppe Valacchi; Palma Specchia; Lucio Gnessi; Elizaveta P Rubanenko; Elena A Shuginina; Arseny I Trukhanov; Liudmila G Korkina; Chiara De Luca
Journal:  Oxid Med Cell Longev       Date:  2015-05-18       Impact factor: 6.543

7.  Amphiregulin activates human hepatic stellate cells and is upregulated in non alcoholic steatohepatitis.

Authors:  Chad McKee; Barbara Sigala; Junpei Soeda; Angelina Mouralidarane; Maelle Morgan; Gianluigi Mazzoccoli; Francesca Rappa; Francesco Cappello; Daniela Cabibi; Valerio Pazienza; Claire Selden; Tania Roskams; Manlio Vinciguerra; Jude A Oben
Journal:  Sci Rep       Date:  2015-03-06       Impact factor: 4.379

8.  Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma.

Authors:  Francesca Rappa; Azzura Greco; Christine Podrini; Francesco Cappello; Michelangelo Foti; Lucie Bourgoin; Marion Peyrou; Arianna Marino; Nunzia Scibetta; Roger Williams; Gianluigi Mazzoccoli; Massimo Federici; Valerio Pazienza; Manlio Vinciguerra
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

9.  SIRT1-metabolite binding histone macroH2A1.1 protects hepatocytes against lipid accumulation.

Authors:  Valerio Pazienza; Michela Borghesan; Tommaso Mazza; Fareeba Sheedfar; Concetta Panebianco; Roger Williams; Gianluigi Mazzoccoli; Angelo Andriulli; Tomoko Nakanishi; Manlio Vinciguerra
Journal:  Aging (Albany NY)       Date:  2014-01       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.